EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies

Giuseppe Lauletta iD, Cataldo Patruno iD, Claudio Brescia iD, Andrea Cosenza, Carolina D'Elia, Valentina Ventura iD, Emanuela Martina, Maddalena Napolitano iD

Antibodies · 05.12.2025 · 14 (4) · 104

DOI: 10.3390/antib14040104 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibodies, online erschienen am 05.12.2025. Verfasst von Giuseppe Lauletta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80128 Naples, Italy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Head and neck dermatitis (HND) represents a challenging phenotype of atopic dermatitis (AD), often showing suboptimal response or paradoxical worsening during biologic therapy.

Objective

To review the efficacy and safety of current systemic treatments for HND, with a focus on dupilumab, tralokinumab, lebrikizumab, and janus kinase (JAK) inhibitors.

Methods

We conducted a narrative review of randomized controlled trials, post hoc analyses, and real-world studies assessing clinical outcomes in patients with moderate-to-severe AD involving the head and neck. Outcomes included Eczema Area and Severity Index (EASI) H&N subscore, erythema grade, patient-reported measures, and adverse events.

Results

Dupilumab shows substantial efficacy for HND in both clinical trials and real-life studies; however, responses are often less pronounced than in other anatomical regions, and facial redness (FR) has emerged as a notable adverse event in up to 9% of patients. Tralokinumab and lebrikizumab demonstrate significant improvements in HND involvement, with low incidence of paradoxical reactions. JAK inhibitors, particularly upadacitinib, provide rapid and marked improvement in refractory cases and in patients developing FR during biologic therapy.

Conclusions

Systemic therapy for HND should be individualized, balancing efficacy and tolerability. JAK inhibitors represent a valuable alternative in biologic-refractory phenotypes or in patients experiencing dupilumab-associated FR.

Schlagwörter

Stichwörter der Autor:innen

JAK inhibitorsatopic dermatitisdupilumabhead and neck dermatitislebrikizumabtralokinumab

Autor:innen und Institutionen

  • Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, 80128 Naples, Italy.
  • Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, 86100 Campobasso, Italy.
  • Dermatology Clinic, Department of Clinical and Molecular Sciences, Polytechnic Marche University, 60121 Ancona, Italy.

ORCID-Profile: Giuseppe Lauletta, Cataldo Patruno, Claudio Brescia, Valentina Ventura, Maddalena Napolitano

Zitieren

APA

Lauletta, G., Patruno, C., Brescia, C., Cosenza, A., D'Elia, C., Ventura, V., Martina, E., & Napolitano, M. (2025). Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies. Antibodies, 14(4), 104. https://doi.org/10.3390/antib14040104

Vancouver

Lauletta G, Patruno C, Brescia C, Cosenza A, D'Elia C, Ventura V, et al. Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies. Antibodies. 2025;14(4):104. doi:10.3390/antib14040104

BibTeX
@article{Lauletta2025,
  author = {Lauletta, Giuseppe and Patruno, Cataldo and Brescia, Claudio and Cosenza, Andrea and D'Elia, Carolina and Ventura, Valentina and Martina, Emanuela and Napolitano, Maddalena},
  title = {Head and Neck Dermatitis in Atopic Dermatitis: A Narrative Review of Pathogenesis, Clinical Challenges, and Therapeutic Strategies},
  journal = {Antibodies},
  year = {2025},
  volume = {14},
  number = {4},
  pages = {104},
  doi = {10.3390/antib14040104}
}
Kostenlos starten →